Javlor
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Vinflunine
- Made by
- Pierre Fabre Medicament
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status ? 2.
EMA’s data export replaced some characters it could not represent (for example “≥”) with “?”. The text is shown exactly as exported; the wording on the EMA page is authoritative.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Pierre Fabre Medicament |
|---|---|
| Active substance | Vinflunine |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01CA05 · Cancer treatments and immune-system medicines |
| Authorised on | 2009-09-21 |
| Last updated by the regulator | 2025-07-16 |
| EMA product number | EMEA/H/C/000983 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).